| Literature DB >> 22943011 |
Abstract
Gastrointestinal stromal tumor has received a lot of attention over the last 10 years due to its unique biologic behavior, clinicopathological features, molecular mechanisms, and treatment implications. GIST is the most common mesenchymal neoplasm in the gastrointestinal tract and has emerged from a poorly understood and treatment resistant neoplasm to a well-defined tumor entity since the discovery of particular molecular abnormalities, KIT and PDGFRA gene mutations. The understanding of GIST biology at the molecular level promised the development of novel treatment modalities. Diagnosis of GIST depends on the integrity of histology, immunohistochemistry and molecular analysis. The risk assessment of the tumor behavior relies heavily on pathological evaluation and significantly impacts clinical management. In this review, historic review, epidemiology, pathogenesis and genetics, diagnosis, role of molecular analysis, prognostic factor and treatment strategies have been discussed.Entities:
Keywords: GIST; Gastrointestinal stromal tumor; KIT mutation; imatinib
Year: 2012 PMID: 22943011 PMCID: PMC3418531 DOI: 10.3978/j.issn.2078-6891.2012.031
Source DB: PubMed Journal: J Gastrointest Oncol ISSN: 2078-6891